Oryzon Genomics S.A. (0RDB.L)
EUR 2.74
(-1.44%)
EUR 2.74
(-1.44%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.89 Million USD | 14.57% |
| 2022 | -5.72 Million USD | 26.84% |
| 2021 | -7.83 Million USD | -54.17% |
| 2020 | -5.07 Million USD | -22.51% |
| 2019 | -4.14 Million USD | -16.85% |
| 2018 | -3.54 Million USD | 35.26% |
| 2017 | -5.48 Million USD | -9.22% |
| 2016 | -5.01 Million USD | -814.37% |
| 2015 | -548.78 Thousand USD | -104.49% |
| 2014 | 12.22 Million USD | 1411.24% |
| 2013 | -932.34 Thousand USD | -760.26% |
| 2012 | 141.2 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 895.34 Thousand USD | -60.38% |
| 2024 Q1 | 2.26 Million USD | -77.73% |
| 2023 Q2 | 2.92 Million USD | 152.71% |
| 2023 FY | - USD | -261.6% |
| 2023 Q1 | -5.55 Million USD | -159.45% |
| 2023 Q4 | -5.01 Million USD | -12.51% |
| 2023 Q3 | -4.45 Million USD | -252.18% |
| 2022 Q2 | 2.75 Million USD | 149.84% |
| 2022 Q1 | -5.53 Million USD | -183.2% |
| 2022 FY | - USD | 26.84% |
| 2022 Q4 | 9.34 Million USD | 290.67% |
| 2022 Q3 | -4.9 Million USD | -277.68% |
| 2021 Q3 | -5.01 Million USD | -397.54% |
| 2021 Q2 | 1.68 Million USD | 130.41% |
| 2021 FY | - USD | -54.17% |
| 2021 Q4 | 6.65 Million USD | 232.67% |
| 2021 Q1 | -5.54 Million USD | -362.43% |
| 2020 Q1 | -1.01 Million USD | -40.25% |
| 2020 FY | - USD | -22.51% |
| 2020 Q4 | -1.19 Million USD | -18.47% |
| 2020 Q3 | -1.01 Million USD | 11.7% |
| 2020 Q2 | -1.14 Million USD | -13.06% |
| 2019 FY | - USD | -16.85% |
| 2019 Q4 | -722.42 Thousand USD | 17.94% |
| 2019 Q2 | -1.3 Million USD | -26.96% |
| 2019 Q1 | -1.02 Million USD | -48.04% |
| 2019 Q3 | -880.39 Thousand USD | 32.33% |
| 2018 Q3 | -837.81 Thousand USD | 15.29% |
| 2018 Q4 | -692.23 Thousand USD | 17.38% |
| 2018 FY | - USD | 35.26% |
| 2018 Q2 | -989.03 Thousand USD | -24.49% |
| 2018 Q1 | -794.47 Thousand USD | 43.84% |
| 2017 Q2 | -1.22 Million USD | -9.89% |
| 2017 Q1 | -1.11 Million USD | 11.49% |
| 2017 Q4 | -1.41 Million USD | -38.24% |
| 2017 Q3 | -1.02 Million USD | 16.52% |
| 2017 FY | - USD | -9.22% |
| 2016 Q3 | -1.12 Million USD | 30.56% |
| 2016 FY | - USD | -814.37% |
| 2016 Q4 | -1.26 Million USD | -12.36% |
| 2016 Q2 | -1.61 Million USD | -100.55% |
| 2016 Q1 | -805.41 Thousand USD | -27.33% |
| 2015 Q4 | -632.52 Thousand USD | -125.15% |
| 2015 Q1 | -688.57 Thousand USD | 2.34% |
| 2015 Q2 | 1.36 Million USD | 298.43% |
| 2015 FY | - USD | -104.49% |
| 2015 Q3 | -280.93 Thousand USD | -120.56% |
| 2014 Q4 | -705.08 Thousand USD | -21.53% |
| 2014 Q2 | 5.85 Million USD | -0.0% |
| 2014 Q3 | -580.15 Thousand USD | -109.91% |
| 2014 FY | - USD | 1411.24% |
| 2014 Q1 | 5.85 Million USD | 0.0% |
| 2013 FY | - USD | -760.26% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Boiron SA | 80.67 Million EUR | 106.067% |
| Laboratorios Farmaceuticos Rovi, S.A. | 238.01 Million EUR | 102.056% |
| Vetoquinol SA | 104.58 Million EUR | 104.68% |
| Valneva SE | -64.51 Million EUR | 92.414% |
| AB Science S.A. | -9.28 Million EUR | 47.264% |
| Nanobiotix S.A. | -34.01 Million EUR | 85.613% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 78.655% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 82.738% |
| BioSenic S.A. | -6.79 Million EUR | 27.981% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 96.326% |
| Formycon AG | 81.05 Million EUR | 106.039% |